[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344203-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344203-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identifying-strong-neoantigen-mhc-iii-binding-candidates-for-targeted-immunotherapy-with-sine-abstract","Identifying Strong Neoantigen MHC-I/II Binding Candidates for Targeted Immunotherapy with SINE - Abstract","","Tumor-derived neoantigens that can bind major histocompatibility complex (MHC-I/II) and elicit immune responses have enabled advances in immunotherapy, yet some cancers show low rates of neoantigen discovery through non-synonymous mutations. This work addresses the need to identify neoantigens from additional mechanisms, particularly aberrant splicing, by introducing the splice isoform neoantigen evaluator (SINE) pipeline. SINE catalogs peptides arising from spliced or inserted genomic regions using Patient Harmonic-mean Best Rank scores and computes MHC-I/II binding across the full HLA landscape. The study identifies 125 potentially immunogenic events and 9 principal binders in head and neck cancer patients lacking MHC affinity for corresponding wild-type peptides. In a melanoma cohort treated with anti-PD1, immunogenic splicing events predicted response, suggesting immune editing. Results show SINE’s capability to identify clinically relevant immunogenic neojunctions and support researchers in mapping the neoantigen landscape from aberrant splicing in cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identifying-strong-neoantigen-mhc-iii-binding-candidates-for-targeted-immunotherapy-with-sine-abstract/344203/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identifying-strong-neoantigen-mhc-iii-binding-candidates-for-targeted-immunotherapy-with-sine-abstract/344203.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is neoantigen identification needed beyond non-synonymous mutations?","Question",{"text":63,"@type":64},"Some cancers have a low rate of neoantigen discovery from non-synonymous mutations. Additional sources like aberrant splicing can generate neoantigens that broaden the detectable neoantigen landscape.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the SINE pipeline used for?",{"text":68,"@type":64},"SINE is a splice isoform neoantigen evaluator pipeline that documents peptides present on spliced or inserted genomic regions of interest and calculates MHC-I/II binding affinity across the full HLA landscape.",{"name":70,"@type":61,"acceptedAnswer":71},"What key findings were reported for head and neck cancer and melanoma cohorts?",{"text":72,"@type":64},"In head and neck cancer patients, SINE found 125 potentially immunogenic events and 9 principal binders where corresponding wild-type peptides show no MHC-I/II affinity. In melanoma patients treated with anti-PD1, immunogenic splicing events identified by SINE predicted response, suggesting immune editing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344203,1790193585,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nIdentifying Strong Neoantigen MHC-I/II Binding Candidates for Targeted Immunotherapy with SINE  \nJoseph Bendik 1, Andrea Castro 1,2, Joseph Califano 1,3,4, Hannah Carter 1,2 and Theresa Guo 1,3,4, *  \nAcademic Editor: Naoyuki Kataoka  \nReceived: 14 December 2024  \nRevised: 18 December 2024  \nAccepted: 25 December 2024  \nPublished: 29 December 2024  \nCitation: Bendik, J.; Castro, A.; Califano, J.; Carter, H.; Guo, T. Identifying Strong Neoantigen MHC-I/II Binding Candidates for Targeted Immunotherapy with SINE. Int. J. Mol. Sci. 2025, 26, 205. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26010205](doi.org/10.3390/ijms26010205)  \n[Copyright:](Copyright:) © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA  \n2 Division of Medical Genetics, Department of Medicine, University of California San Diego, San Diego, CA 92093, USA  \n3 Gleiberman Head and Neck Cancer Center, University of California San Diego, San Diego CA 92037, USA  \n4 Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego, San Diego, CA 92037, USA  \n* Correspondence: [twguo@health.ucsd.edu](twguo@health.ucsd.edu)  \nAbstract: The discovery of tumor-derived neoantigens which elicit an immune response through major histocompatibility complex (MHC-I/II) binding has led to significant advancements in immunotherapy. While many neoantigens have been discovered through the identification of non-synonymous mutations, the rate of these is low in some cancers, including head and neck squamous cell carcinoma. Therefore, the identification of neoantigens through additional means, such as aberrant splicing, is necessary. To achieve this, we developed the splice isoform neoantigen evaluator (SINE) pipeline. Our tool documents peptides present on spliced or inserted genomic regions of interest using Patient Harmonic-mean Best Rank scores, calculating the MHC-I/II binding affinity across the complete human leukocyte antigen landscape. Here, we found 125 potentially immunogenic events and 9 principal binders in a cohort of head and neck cancer patients where the corresponding wild-type peptides display no MHC-I/II affinity. Further, in a melanoma cohort of patients treated with anti-PD1 therapy, the expression of immunogenic splicing events identified by SINE predicted response, potentially indicating the existence of immune editing in these tumors. Overall, we demonstrate SINE’s ability to identify clinically relevant immunogenic neojunctions, thus acting as a useful tool for researchers seeking to understand the neoantigen landscape from aberrant splicing in cancer.  \nKeywords: alternative splicing; head and neck cancer; melanoma; neoantigen; targeted immunotherapy response; software  \n1. Introduction  \nIn recent years, the immune checkpoint blockade, especially the development of programed cell death receptor (PD-1) inhibitors, has emerged as a revolution in cancer therapy. Often, tumor cells can express higher levels of programmed cell death receptor–ligand 1 (PD-L1), which then binds to PD-1 on T-Cells, suppressing immune system activity [1] . The development of checkpoint inhibitor drugs such as nivolumab and pembrolizumab have allowed for the blockade of these checkpoints, opening the door for immune-mediated tumor killing [2] . However, many patients remain unresponsive to these treatments. The causes are postulated to be due to a variety of potential factors such as a lack of tumor antigen recognition, defective effector T cell function, and/or microenvironment differences [3,4] .  \nBecause of these limitations, the discovery of novel tumor-derived neoa","cbCaibf4eT7QKJds","https://ap.wps.com/l/cbCaibf4eT7QKJds","pdf",1699704,18,"English","# Introduction\n## Immunotherapy and immune checkpoint blockade\n## Need for novel neoantigen discovery beyond mutations\n## Aberrant splicing as an underexplored neoantigen source","[{\"question\":\"Why is neoantigen identification needed beyond non-synonymous mutations?\",\"answer\":\"Some cancers have a low rate of neoantigen discovery from non-synonymous mutations. Additional sources like aberrant splicing can generate neoantigens that broaden the detectable neoantigen landscape.\"},{\"question\":\"What is the SINE pipeline used for?\",\"answer\":\"SINE is a splice isoform neoantigen evaluator pipeline that documents peptides present on spliced or inserted genomic regions of interest and calculates MHC-I/II binding affinity across the full HLA landscape.\"},{\"question\":\"What key findings were reported for head and neck cancer and melanoma cohorts?\",\"answer\":\"In head and neck cancer patients, SINE found 125 potentially immunogenic events and 9 principal binders where corresponding wild-type peptides show no MHC-I/II affinity. In melanoma patients treated with anti-PD1, immunogenic splicing events identified by SINE predicted response, suggesting immune editing.\"}]","Identifying Strong Neoantigen MHC-I/II Binding Candidates for Targeted Immunotherapy with SINE - Abstract | PDF",1790053216,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4cc4ce70e68b51858839f144f116285.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b1496bcaa9a884d82771092f16e45e3.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aef5b3e7a116a62720b9019a0b545229.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80fbf42383118a0fa4283a7eca3a9468.webp",980,1385]